GoCART

Revolutionizing CAR T-cell therapy with decentralized science. Targeting Acute Myeloid Leukemia and beyond!

[GoCART @GoCART_Tx]

$5.9B → $16.1B by 2030. But the more important story is where the gaps still are.

All approved CAR-T products target just two antigens — CD19 and BCMA. Every indication they cover shares one thing: a target specific enough to hit safely with a single input.

AML doesn't have that antigen. CD33, CD123, CLL-1 are all well-validated — but none are exclusive enough to use alone without damaging healthy bone marrow.

The next step is clear: require two signals instead of one. Activate only when both markers appear on the same cell.

That's the architecture GoCART is building.

#CellTherapy #CART #AML #Immunotherapy #Oncology #GoCART

[GoCART @GoCART_Tx]

CD56 is one of the most potent cancer targets in MM and AML. It's also been off-limits for years.

The problem: CD56 isn't tumor-exclusive. It's also expressed on NK cells, peripheral neurons, and muscle tissue. Single-antigen CAR-T can't tell the difference — the result is severe neurotoxicity and NK cell depletion. That's what "undruggable" actually means.

The fix isn't a safer binder. It's a smarter gate.

Require CD56 + a second antigen on the same cell. Neurons carry CD56, not CD38. NK cells carry CD56, not CD33. Tumor cells carry both.

GoCART pairs CD56 with CD38 in MM and CD33 in AML. Same target. Two keys instead of one.

The antigen was never the problem. The logic was.
#CellTherapy #CART #Immunotherapy #MultipleMyeloma #AML #GoCART

[GoCART @GoCART_Tx]

@maxhodak_ I've been tracking your first-principles work @ScienceCorp_. We’re taking a similar engineering approach to "undruggable" AML targets. We’ve funneled an 180k sequence library down to 20 prime candidates for logic-gated activation and are raising a $150k bridge to execute in vitro validation in Spain (Cádiz). Our SRA guarantees the patent moat on the resulting assets. Would you be open to a 10-minute brief on how we’re solving the "leakiness" problem in extracellular AND-gates?

[GoCART @GoCART_Tx]

Acute Myeloid Leukemia remains one of the most difficult cancers for CAR-T therapy, not because AML lacks targets, but because no single target is truly safe.

CD33, CD123, FLT3 and CLL-1 are all promising, but each is also expressed on healthy hematopoietic tissue.

This creates the central challenge in AML: a therapy strong enough to eliminate leukemia may also damage the normal bone marrow required for recovery.

AML is also highly heterogeneous. Different patients and even different leukemic subclones can express different antigen profiles or lose a target under treatment pressure.

As a result, AML is unlikely to be solved by a single-antigen approach.

The future may depend on therapies capable of recognizing combinations of signals uniquely associated with leukemic cells.

That is the principle behind GoCART and its multi-antigen recognition strategy.

#AML #CART #CellTherapy #Biotech #Immunotherapy

[GoCART @GoCART_Tx]

Unprecedented kill speed, but durability remains the ghost in the machine. This MGH data confirms the industry's current ceiling: we have the potency, but we lack the spatial logic to prevent recurrence.

@GoCART_Tx , we are building the biological AND-gates required to move from 'temporary regression' to clinical survival. Precision is the only way forward.

[Massimo @Rainmaker1973]

A single dose of a new cancer drug made a brain tumor almost disappear – in just five days.

Doctors at Massachusetts General Hospital reported “dramatic and rapid” tumor regression in the first patients treated with a next-generation form of CAR T-cell therapy for glioblastoma, one of the most aggressive brain cancers known.

The therapy, called CARv3-TEAM-E, was developed to overcome a major hurdle in treating solid tumors: their ability to hide from the immune system.

The personalized treatment reprograms a patient’s immune cells to attack the tumor, and in one extraordinary case, nearly eliminated the cancer within just five days. This novel therapy is designed to target multiple features of the tumor at once, a strategy that may help overcome the common challenge of treatment resistance in solid tumors like glioblastoma.

Although the tumors eventually returned, the early outcomes were described as unprecedented. One patient saw a 60% reduction in tumor size that lasted for half a year—an impressive result in a cancer known for its aggressiveness.

The trial’s success marks a major step forward for immunotherapy in brain cancer and raises new hopes for long-term control or even a cure. Researchers are now working to refine the treatment and extend its effects, with the ultimate goal of turning a once-terminal diagnosis into a survivable condition.

[GoCART @GoCART_Tx]

We're bringing our biologics solutions to @festofbiologics! Visit Booth #S8 to connect, share ideas, and spark innovation.

Reserve your spot: https://t.co/5uR6TdNepq
#festivalofbiologicsUSA #BiologicsSolutions #Networking

[GoCART @GoCART_Tx]

We're thrilled to be at @festofbiologics USA 2026! Visit Booth S8 to explore our latest biologics innovations & connect with our team.

Join Us – Register Here: https://t.co/sU7wiGrjBO

#festivalofbiologicsUSA

[GoCART @GoCART_Tx]

Intelligence Leap - 5th gen CAR T and safety By Design https://t.co/DbnMiTa3kS

[GoCART @GoCART_Tx]

🔗 Set a reminder: https://t.co/72GTyKXPMf

Traditional CAR-T has hit a safety ceiling. We aren't searching for safety; we are engineering it.

Join the Brain Trust this Tuesday for a deep dive into the 5th-gen, logic-gated architecture designed to physically bypass the toxicity barrier in immunotherapy.

The Panel:
🧬 Henry Erdlei (@GoCART_DeSci)
🧬 Dr. Francisco Garcia-Cozar (@currogarco)
🧬 George Eastwood (@gge513)
🧬 Stefan Munker, MD (@munker99105)
🎙️ Moderated by @AliusPascal

🗓️ Tuesday, Feb 3⏰ 9:00 AM MST | 16:00 UTC | 17:00 CET

#Biotech #Immunotherapy #Oncology #GoCART #SafetyByDesign

[GoCART @GoCART_Tx]

95% ORR in DLBCL is a milestone. The physiological cost is not. 🧬

However, moving this success toward even more aggressive challenges like Acute Myeloid Leukemia (AML) requires a fundamental shift in how we manage toxicity.

At GoCART, we’re shifting to Safety by Design. Our AND-gate is engineered to:
✅ Require dual-antigen confirmation (critical for AML)
✅ Dramatically reduce the duration/dosage of steroids ✅ Calibrate activation to avoid "over-activation" even in high tumor burden

Precision is how we expand the therapeutic window for patients with no safe options today.

👉 To learn more about the technical specifications of our AND-gate technology, join our professional community on Discord: https://t.co/KXPBGtHufI

#Biotech #GoCART #CARTcell #Oncology

[GoCART @GoCART_Tx]

95% Overall Response Rate (ORR) is a milestone. The physiological cost is not.

Anti-CD19 CAR-Ts hit 95% ORR, but the systemic price remains devastating. As documented by Brudno & Kochenderfer (Blood 2016), T-cell activation can trigger a "cascade of failure" across vital organs:

🫀 Heart: tachycardia & decreased ejection fraction.
🧪 Liver/Kidney: severe transaminitis & acute injury.
🩸 Blood: DIC & systemic inflammatory stress.

Current protocols rely on reactive immunosuppression to manage these events. We need a shift to Safety by Design.

At GoCART, our AND-gate ensures activation only on the tumor, sparing healthy organs. Precision is the only way to move from managing toxicity to engineering safety.

👉 To learn more about the technical specifications of our AND-gate technology, join our professional community on Discord: https://t.co/KXPBGtHufI

[GoCART @GoCART_Tx]

❗️In the fight against Acute Myeloid Leukemia (AML), CD33 has long been the primary target for researchers. It is expressed in over 90% of AML cases, making it a nearly universal marker for therapy. However, the clinical utility of targeting CD33 is restricted by its presence on healthy hematopoietic stem and progenitor cells (HSPCs). In standard CAR-T applications, this overlap often leads to significant "on-target, off-tumor" toxicity, resulting in prolonged myelosuppression that can severely hinder a patient's recovery.

GoCART is building next-generation AND-gate CAR-T systems for AML to solve this. We require the simultaneous recognition of two antigens to ensure the therapy spares healthy cells and preserves the patient’s hematologic system.

👉 To learn more about the technical specifications of our AND-gate technology, join our professional community on Discord: https://t.co/KXPBGtHufI

[GoCART @GoCART_Tx]

90%+ response rates and relapse still wins.

That’s the paradox of CAR-T in multiple myeloma📌

It’s one of the most clinically advanced indications for cell therapy, yet the disease almost always comes back.
Why? Under sustained single-target pressure, myeloma cells adapt, changing antigen expression and allowing resistant clones to expand.

The real question in multiple myeloma is no longer whether CAR-T works. It’s how to design systems that can adapt as the disease evolves - the design space GoCART is working in.

👉 To learn how we’re approaching this challenge, join our Discord: https://t.co/KXPBGtGWqa

[GoCART @GoCART_Tx]

In AML, most antigens aren’t tumor-specific: they’re shared with healthy myeloid cells and even hematopoietic stem cells.

That makes single-target CAR-T inherently unsafe. AML isn’t a targeting problem, it’s a logic problem.

👉 To learn how we’re solving this, join our Discord: https://t.co/KXPBGtHufI

[GoCART @GoCART_Tx]

Stability is the foundation of efficacy. Our Auto Predictor ensures that our recognition sequences don't just bind—they stay stable in complex tumor environments. Our current pilot AND-Gates meet rigorous safety thresholds to ensure consistent performance.

🧬Join the mission: https://t.co/KXPBGtHufI

[GoCART @GoCART_Tx]

70% of cancers currently lack a targetable, unique antigen. This is why CAR-T has remained limited to blood cancers. GoCART is building the "chassis" to unlock those 70% by making dual-targeting reliable and safe. #Oncology #Biotech

Join the mission: https://t.co/rZxrbxT7KG

[GoCART @GoCART_Tx]

Why does an "AND-gate" matter? Current CAR-T can be a "blunt instrument," sometimes attacking healthy tissue. Our system requires TWO keys to turn the "kill" signal on. No second signal = no attack. Safety by design. 🛡️

Learn more: https://t.co/rZxrbxT7KG

[GoCART @GoCART_Tx]

Building a global biotech startup from Denver to Spain requires relentless coordination. While the lab work happens in Cádiz, our operations focus on one goal: ensuring our "AND-gate" chassis is scalable and compliant for the patients who need it most. 🌍💻

Join the mission: https://t.co/KXPBGtHufI